Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate

Ylva Ginsberg, Tatja Hirvikoski, Martin Grann, Nils Lindefors, Ylva Ginsberg, Tatja Hirvikoski, Martin Grann, Nils Lindefors

Abstract

In a recent randomized, double-blind, placebo-controlled trial, we established a robust efficacy (Cohen's d = 2.17) of osmotic release oral system-methylphenidate (OROS-methylphenidate) delivered 72 mg daily for 5 weeks versus placebo on attention deficit hyperactivity disorder (ADHD) symptoms, global severity and global functioning in 30 adult male prison inmates with ADHD and coexisting disorders. Outcomes continued to improve during the subsequent 47-week open-label extension with OROS-methylphenidate delivered at a flexible daily dosage of up to 1.3 mg/kg body weight. In the present study, we evaluated long-term effectiveness and maintenance of improvement over the cumulated 52-week trial on cognition, motor activity, institutional behaviour and quality of life. Post hoc, we explored the associations between investigators' and self-ratings of ADHD symptoms and between ratings of symptoms and functioning, respectively. Outcomes, calculated by repeated measures ANOVA, improved from baseline until week 16, with maintenance or further improvement until week 52. Both verbal and visuospatial working memory, and abstract verbal reasoning improved significantly over time, as well as several cognition-related measures and motor activity. No substance abuse was detected and a majority of participants took part in psychosocial treatment programmes. The quality of life domains of Learning, and Goals and values improved over time; the latter domain was at open-label endpoint significantly related to improvements in attention. Investigators' and self-ratings of ADHD symptoms, as well as global symptom severity related most significantly to global functioning at week 52. Finally, investigators' and self-ratings of ADHD symptoms associated significantly at baseline with increasing convergence over time.

Figures

Fig. 1
Fig. 1
Study flow chart of participants in the cumulative 52-week trial
Fig. 2
Fig. 2
Both verbal working memory (Digit Span, panel to the left) and visuospatial working memory (Span Board, panel to the right) improved over time. The largest improvements were observed from baseline until study week 16. Data from completers (n = 25) are presented in the figure. Note: Asterisk indicates the effect on repeated measure P < 0.05
Fig. 3
Fig. 3
Seven out of twelve measures in the Conners’ Continuous Performance Test II improved. Five participants with extreme values at baseline (T-score >200) were excluded in the figure. Data from completers (n = 21) are presented in the figure; baseline data were missing for three participants due to technical error
Fig. 4
Fig. 4
Motor activity and cognition-related measures improved significantly over time as measured by QbTest. Data from completers, n = 23 (one missing data due to technical error) and n = 24, respectively, are presented as age- and sex-scaled scores with a population mean of 0 (M = 0) and a standard deviation of 1 (SD = 1)

References

    1. de Zwaan M, Gruß B, Müller A, Graap H, Martin A, Glaesmer H, Hilbert A, Philipsen A. The estimated prevalence and correlates of adult ADHD in a German community sample. Eur Arch Psychiatry Clin Neurosci. 2012;262:79–86. doi: 10.1007/s00406-011-0211-9.
    1. Swanson J, Baler RD, Volkow ND. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology. 2011;36:207–226. doi: 10.1038/npp.2010.160.
    1. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159–165. doi: 10.1017/S003329170500471X.
    1. Lis S, Baer N, Stein-en-Nosse C, Gallhofer B, Sammer G, Kirsch P. Objective measurement of motor activity during cognitive performance in adults with attention-deficit/hyperactivity disorder. Acta Psychiatr Scand. 2010;122:285–294. doi: 10.1111/j.1600-0447.2010.01549.x.
    1. Kooij SJJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10:67. doi: 10.1186/1471-244X-10-67.
    1. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005;57:1336–1467. doi: 10.1016/j.biopsych.2005.02.006.
    1. Kebir O, Joober R. Neuropsychological endophenotypes in attention-deficit/hyperactivity disorder: a review of genetic association studies. Eur Arch Psychiatry Clin Neurosci. 2011;261:583–594. doi: 10.1007/s00406-011-0207-5.
    1. Cherkasova MV, Hechtman L. Neuroimaging in attention-deficit hyperactivity disorder: beyond the frontostriatal circuitry. Can J Psychiatry. 2009;54:651–664.
    1. Castellanos FX, Proal E. Large-scale brain systems in ADHD: beyond the prefrontal–striatal model. Trends Cogn Sci. 2012;16:17–26. doi: 10.1016/j.tics.2011.11.007.
    1. Fassbender C, Schweitzer JB. Is there evidence for neural compensation in attention deficit hyperactivity disorder? A review of the functional neuroimaging literature. Clin Psychol Rev. 2006;26:445–465. doi: 10.1016/j.cpr.2006.01.003.
    1. Retz W, González-Trejo E, Römer KD, Philipp-Wiegmann F, Reinert P, Low YF, Boureghda S, Rösler M, Strauss DJ (2012) Assessment of post-excitatory long-interval cortical inhibition in adult attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. doi:10.1007/s00406-012-0299-6
    1. Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, Johnston JA, Spencer T. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47:565–572. doi: 10.1097/01.jom.0000166863.33541.39.
    1. Gjervan B, Torgersen T, Nordahl HM, Rasmussen K (2011) Functional impairment and occupational outcome in adults with ADHD. J Atten Disord. doi:10.1177/1087054711413074
    1. Cumyn L, French L, Hechtman L. Comorbidity in adults with attention-deficit hyperactivity disorder. Can J Psychiatry. 2009;54:673–683.
    1. Ginsberg Y, Hirvikoski T, Lindefors N. Attention deficit hyperactivity disorder (ADHD) among longer-term prison inmates is a prevalent, persistent and disabling disorder. BMC Psychiatry. 2010;10:112. doi: 10.1186/1471-244X-10-112.
    1. Rösler M, Retz W, Retz-Junginger P, Hengesch G, Schneider M, Supprian T, Schwitzgebel P, Pinhard K, Dovi-Akue N, Wender P, Thome J. Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci. 2004;254:365–371. doi: 10.1007/s00406-004-0516-z.
    1. Young SJ, Adamou M, Bolea B, Gudjonsson G, Müller U, Pitts M, Thome J, Asherson P. The identification and management of ADHD offenders within the criminal justice system: a consensus statement from the UK Adult ADHD Network and criminal justice agencies. BMC Psychiatry. 2011;11:32. doi: 10.1186/1471-244X-11-32.
    1. Rösler M. Adult attention-deficit hyperactivity disorder—functional impairment, conduct problems and criminality. In: Retz W, Klein RG, editors. Attention-deficit hyperactivity disorder (ADHD) in adults. Basel: Karger; 2010. pp. 144–158.
    1. National Institute for Clinical Excellence . Attention deficit hyperactivity disorder: the NICE guideline on diagnosis and management of ADHD in children, young people and adults. London: The British Psychological Society and the Royal College of Psychiatrists; 2009.
    1. Rösler M, Casas M, Konofal E, Buitelaar J. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry. 2010;11:684–698. doi: 10.3109/15622975.2010.483249.
    1. Molina BSG, Hinshaw SP, Swanson JM, Eugene L, Ed M, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L, Abikoff HB, Elliott GR, Greenhill LL, Newcorn JH, Wells KC, Wigal T, Gibbons RD, Hur K, Houck PR, Mta T. The MTA at 8 years: prospective follow-up of children treated for combined type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48:484–500. doi: 10.1097/CHI.0b013e31819c23d0.
    1. Abikoff H, Hechtman L, Klein RG, Weiss G, Fleiss K, Etcovitch J, Cousins L, Greenfield B, Martin D, Pollack S. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43:802–811. doi: 10.1097/.
    1. Powers RL, Marks DJ, Miller CJ, Newcorn JH, Halperin JM. Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome. J Am Acad Child Adolesc Psychiatry. 2008;18:449–459.
    1. Adler LA, Orman C, Starr HL, Silber S, Palumbo J, Cooper K, Berwaerts J, Harrison DD. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. J Clin Psychopharmacol. 2011;31:108–114. doi: 10.1097/JCP.0b013e318203ea0a.
    1. Bejerot S, Rydén EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J Clin Psychiatry. 2010;71:1590–1597. doi: 10.4088/JCP.09m05168pur.
    1. Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009;259:120–129. doi: 10.1007/s00406-008-0845-4.
    1. Wender PH, Reimherr FW, Marchant BK, Sanford ME, Czajkowski LA, Tomb D. A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord. 2011;15:36–45. doi: 10.1177/1087054709356188.
    1. Wilens TE, Morrison NR, Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother. 2011;11:1443–1465. doi: 10.1586/ern.11.137.
    1. Brams M, Moon E, Pucci M, López F. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin. 2010;26:1809–1825. doi: 10.1185/03007995.2010.488553.
    1. Surman CBH, Monuteaux MC, Petty CR, Faraone SV, Spencer TJ, Chu NF, Biederman J. Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study. J Clin Psychiatry. 2010;71:1612–1616. doi: 10.4088/JCP.09m05344pur.
    1. Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol. 2009;23:733–744. doi: 10.1177/0269881108092338.
    1. Rhodes SM, Coghill DR, Matthews K. Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II–broader executive and non-executive domains. J Child Psychol Psychiatry. 2006;47:1184–1194. doi: 10.1111/j.1469-7610.2006.01633.x.
    1. Coghill DR, Rhodes SM, Matthews K. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;62:954–962. doi: 10.1016/j.biopsych.2006.12.030.
    1. Pietrzak RH, Mollica CM, Maruff P, Snyder PJ. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev. 2006;30:1225–1245. doi: 10.1016/j.neubiorev.2006.10.002.
    1. Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD) Neurosci Biobehav Rev. 2010;34:1256–1266. doi: 10.1016/j.neubiorev.2010.03.006.
    1. Rösler M, Ginsberg Y, Arngrim T, Adamou M, Niemelä A, Dejonkheere J, van Oene J, Schäuble B (2011) Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate. World J Biol Psychiatry [Epub ahead of print]
    1. Fallu A, Richard C, Prinzo R, Binder C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin. 2006;22:2557–2566. doi: 10.1185/030079906X154132.
    1. Buitelaar JK, Casas M, Philipsen A, Kooij JJS, Ramos-Quiroga JA, Dejonckheere J, van Oene JC, Schäuble B. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate. Psychol Med. 2012;42:195–204. doi: 10.1017/S0033291711000845.
    1. Adler LA, Faraone SV, Spencer TJ, Michelson D, Reimherr FW, Glatt SJ, Marchant BK, Biederman J. The reliability and validity of self- and investigator ratings of ADHD in adults. J Atten Disord. 2008;11:711–719. doi: 10.1177/1087054707308503.
    1. Ginsberg Y, Lindefors N. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. Br J Psychiatry. 2012;200:68–73. doi: 10.1192/bjp.bp.111.092940.
    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders (DSM-IV) 4. Washington: APA; 1994.
    1. Lobbestael J, Leurgans M, Arntz A. Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II) Clin Psychol Psychother. 2011;18:75–79. doi: 10.1002/cpp.693.
    1. Hare RD, Clark D, Grann M, Thornton D. Psychopathy and the predictive validity of the PCL-R: an international perspective. Behav Sci Law. 2000;18:623–645. doi: 10.1002/1099-0798(200010)18:5<623::AID-BSL409>;2-W.
    1. Paunovic N, Öst L-G. Clinical validation of the Swedish version of the Quality of Life Inventory in crime victims with posttraumatic stress disorder and a nonclinical sample. Psychopathology. 2004;26:15–21.
    1. Wechsler D. WAIS-III administration and scoring manual. San Antonio: The Psychological Corporation; 1997.
    1. Kaplan E, Fein D, Morris R, Delis D. WAIS-R as a neuropsychological instrument. New York: The Psychological Corporation; 1991.
    1. Conners CK. Manual for the Conners’ Continuous Performance Test-II. Tonawanda: Multi-Health Systems; 2002.
    1. Frisch MB, Cornell J, Villanueva M, Retzlaff PJ. Clinical validation of the Quality of Life Inventory. A measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess. 1992;4:92–101. doi: 10.1037/1040-3590.4.1.92.
    1. Frisch MB, Clark MP, Rouse SV, Rudd MD, Paweleck JK, Greenstone A, Kopplin D. Predictive and treatment validity of life satisfaction and the quality of life inventory. Assessment. 2005;12:66–78. doi: 10.1177/1073191104268006.
    1. Eng W, Coles ME, Heimberg RG, Safren S. Domains of life satisfaction in social anxiety disorder: relation to symptoms and response to cognitive-behavioral therapy. J Anxiety Disord. 2005;19:143–156. doi: 10.1016/j.janxdis.2004.01.007.
    1. Rösler M, Retz W, Stieglitz R-D. Psychopathological rating scales as efficacy parameters in adult ADHD treatment investigations—benchmarking instruments for international multicentre trials. Pharmacopsychiatry. 2010;43:92–98. doi: 10.1055/s-0029-1242819.
    1. Guy W. Clinical global impressions. Rockville: US Department of Health and Human Services; 1976.
    1. Ramirez A, Ekselius L, Ramklint M. Axis V—Global Assessment of Functioning scale (GAF), further evaluation of the self-report version. Eur Psychiatry. 2008;23:575–579. doi: 10.1016/j.eurpsy.2008.05.001.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2. Hillsdale: Lawrence Erlbaum Associates; 1988.
    1. Dickstein S, Bannon K, Castellanos FX, Milham MP. The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis. J Child Psychol Psychiatry. 2006;47:1051–1062. doi: 10.1111/j.1469-7610.2006.01671.x.
    1. Fassbender C, Zhang H, Buzy WM, Cortes CR, Mizuiri D, Beckett L, Schweitzer JB. A lack of default network suppression is linked to increased distractibility in ADHD. Brain Res. 2009;1273:114–128. doi: 10.1016/j.brainres.2009.02.070.
    1. Wehmeier PM, Schacht A, Wolff C, Otto WR, Dittmann RW, Banaschewski T. Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device. J Child Adolesc Psychopharmacol. 2011;21:433–444. doi: 10.1089/cap.2010.0142.
    1. Vogt C, Williams T. Early identification of stimulant treatment responders, partial responders and non-responders using objective measures in children and adolescents with hyperkinetic disorder. Child Adolesc Mental Health. 2011;16:144–149. doi: 10.1111/j.1475-3588.2010.00593.x.
    1. Young S, Gudjonsson G, Wells J, Asherson P, Theobald D, Oliver B, Scott C. Attention deficit hyperactivity disorder and critical incidents in a Scottish prison population. Pers Individ Diff. 2009;46:265–269. doi: 10.1016/j.paid.2008.10.003.
    1. Young S, Thome J. ADHD and offenders. World J Biol Psychiatry Suppl. 2011;1:124–128.
    1. Young S, Chick K, Gudjonsson G. A preliminary evaluation of reasoning and rehabilitation 2 in mentally disordered offenders (R&R2M) across two secure forensic settings in the United Kingdom. J Forensic Psychiatry Psychol. 2010;21:336–349. doi: 10.1080/14789940903513203.
    1. Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS drugs. 2010;24:843–866. doi: 10.2165/11537450-000000000-00000.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner